{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T07:10:06Z","timestamp":1772953806643,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1402\\u20132\\u2013107\\u201351,817"],"award-info":[{"award-number":["1402\\u20132\\u2013107\\u201351,817"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.retram.2025.103534","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:11:28Z","timestamp":1754493088000},"page":"103534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy with ex vivo\u2013expanded donor-derived NK cells after haploidentical HSCT in pediatric patients with AML: a phase I pilot study"],"prefix":"10.1016","volume":"73","author":[{"given":"Tahereh","family":"Rostami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Chahardoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Azari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Azari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Kiumarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghasem","family":"Janbabaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.retram.2025.103534_bib0001","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-020-01063-2","article-title":"Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia","volume":"56","author":"Saglio","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.retram.2025.103534_bib0002","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ajh.24963","article-title":"Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation","volume":"93","author":"Canaani","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.retram.2025.103534_bib0003","first-page":"843","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant? Blood","volume":"124","author":"Wang","year":"2014","journal-title":"J Am Society of Hematol"},{"key":"10.1016\/j.retram.2025.103534_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0265-2","article-title":"How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?","volume":"9","author":"Chang","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.retram.2025.103534_bib0005","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.31941","article-title":"Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over","volume":"125","author":"Santoro","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.retram.2025.103534_bib0006","article-title":"Haploidentical stem cell transplantation with a novel conditioning regimen in older patients: a prospective single-arm phase 2 study","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.retram.2025.103534_bib0007","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/ajh.25934","article-title":"Impact of total body irradiation-vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia","volume":"95","author":"Dholaria","year":"2020","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.retram.2025.103534_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.retram.2025.103534_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Bio Blood and Marrow Transplant"},{"issue":"2","key":"10.1016\/j.retram.2025.103534_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOH.0000000000000412","article-title":"Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?","volume":"25","author":"Liu","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1016\/j.retram.2025.103534_bib0011","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.retram.2025.103534_bib0012","first-page":"3256","article-title":"Risk stratification\u2013directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood","volume":"119","author":"Yan","year":"2012","journal-title":"J Am Society of Hematol"},{"issue":"4","key":"10.1016\/j.retram.2025.103534_bib0013","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbmt.2013.11.028","article-title":"Immune reconstitution after haploidentical hematopoietic stem cell transplantation","volume":"20","author":"Chang","year":"2014","journal-title":"Bio Blood and Marrow Transplantat"},{"issue":"7","key":"10.1016\/j.retram.2025.103534_bib0014","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/cid\/ciz368","article-title":"First-line therapy with donor-derived human cytomegalovirus (HCMV)\u2013specific t cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation","volume":"70","author":"Zhao","year":"2020","journal-title":"Clin Inf Diseases"},{"issue":"24","key":"10.1016\/j.retram.2025.103534_bib0015","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/bloodadvances.2019000242","article-title":"Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Zhao","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2025.103534_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.758512","article-title":"Haploidentical stem cell transplantation for acute myeloid leukemia: current therapies, challenges and future prospective","volume":"11","author":"Chang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.retram.2025.103534_bib0017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12865-023-00548-1","article-title":"Investigation of KIR\/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)","volume":"24","author":"Bakhtiari","year":"2023","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.retram.2025.103534_bib0018","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjh.16355","article-title":"The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience","volume":"188","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.retram.2025.103534_bib0019","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/jcm11010253","article-title":"Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives","volume":"11","author":"Leotta","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.retram.2025.103534_bib0020","series-title":"Hematopoietic cell transplantation for malignant conditions","first-page":"395","article-title":"Principles and applications of cellular therapy in the setting of hematopoietic cell transplant","author":"Khan","year":"2019"},{"key":"10.1016\/j.retram.2025.103534_bib0021","author":"Robertson","year":"1990","journal-title":"Biology and clinical relevance of human natural killer cells"},{"issue":"10","key":"10.1016\/j.retram.2025.103534_bib0022","first-page":"1053","article-title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood","volume":"131","author":"Cooley","year":"2018","journal-title":"J Am Society of Hematol"},{"issue":"3","key":"10.1016\/j.retram.2025.103534_bib0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.0001-2815.2004.00182.x","article-title":"The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD","volume":"63","author":"Bishara","year":"2004","journal-title":"Tissue Antigens"},{"issue":"5562","key":"10.1016\/j.retram.2025.103534_bib0024","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.retram.2025.103534_bib0025","first-page":"1857","article-title":"Phase 1 clinical trial using mbIL21 ex vivo\u2013expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood J Am Society of Hematol"},{"issue":"2","key":"10.1016\/j.retram.2025.103534_bib0026","first-page":"247","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood","volume":"131","author":"Russo","year":"2018","journal-title":"J Am Society of Hematol"},{"issue":"6","key":"10.1016\/j.retram.2025.103534_bib0027","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.retram.2025.103534_bib0028","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","article-title":"Donor-derived natural killer cells infused after human leukocyte antigen\u2013haploidentical hematopoietic cell transplantation: a dose-escalation study","volume":"20","author":"Choi","year":"2014","journal-title":"Bio Blood and Marrow Transplant"},{"issue":"1","key":"10.1016\/j.retram.2025.103534_bib0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.retram.2025.103534_bib0030","first-page":"1670","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood","volume":"139","author":"Bednarski","year":"2022","journal-title":"J Am Society of Hematol"},{"issue":"1","key":"10.1016\/j.retram.2025.103534_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter Standardization of Acute graft-versus-Host disease clinical Data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.retram.2025.103534_bib0032","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biology of Blood and Marrow Transplant"},{"issue":"12","key":"10.1016\/j.retram.2025.103534_bib0033","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Bio Blood and Marrow Transplant"},{"key":"10.1016\/j.retram.2025.103534_bib0034","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.1182\/blood-2023-189400","volume":"142","author":"Dur\u00e1n","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2025.103534_bib0035","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2025.103534_bib0036","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4049\/jimmunol.1801489","article-title":"Impact of KIR\/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell\u2013replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide","volume":"202","author":"Willem","year":"2019","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.retram.2025.103534_bib0037","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41375-018-0170-5","article-title":"Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide","volume":"33","author":"Shimoni","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.retram.2025.103534_bib0038","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbmt.2009.11.022","article-title":"Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"16","author":"Symons","year":"2010","journal-title":"Bio Blood and Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2025.103534_bib0039","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Bio Blood and Marrow Transplant"},{"issue":"11","key":"10.1016\/j.retram.2025.103534_bib0040","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1172\/JCI74337","article-title":"Cytokine therapy reverses NK cell anergy in MHC-deficient tumors","volume":"124","author":"Ardolino","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.retram.2025.103534_bib0041","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cells13050451","article-title":"Building a better defense: expanding and improving natural killer cells for adoptive cell therapy","volume":"13","author":"Maia","year":"2024","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.retram.2025.103534_bib0042","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Bio Blood and Marrow Transplant"},{"issue":"357","key":"10.1016\/j.retram.2025.103534_bib0043","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.retram.2025.103534_bib0044","first-page":"784","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell\u2013depleted stem cell transplantation. Blood","volume":"125","author":"Shah","year":"2015","journal-title":"J Am Society of Hematol"},{"issue":"6","key":"10.1016\/j.retram.2025.103534_bib0045","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.4049\/jimmunol.167.6.3129","article-title":"Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15","volume":"167","author":"Dunne","year":"2001","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.retram.2025.103534_bib0046","first-page":"2515","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood","volume":"131","author":"Romee","year":"2018","journal-title":"J Am Society Hematol"},{"issue":"12","key":"10.1016\/j.retram.2025.103534_bib0047","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/ajh.25983","article-title":"NK cell alloreactivity in acute myeloid leukemia in the post-transplant cyclophosphamide era","volume":"95","author":"Van Elssen","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.retram.2025.103534_bib0048","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.27281","article-title":"Results of a phase I trial with haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML","volume":"99","author":"Ciurea","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:46:30Z","timestamp":1772912790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2452318625000431"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103534","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy with ex vivo\u2013expanded donor-derived NK cells after haploidentical HSCT in pediatric patients with AML: a phase I pilot study","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103534"}}